Sponsored LinkedIn post
A dedicated post to introduce your brand to my audience.
Yonnie Otieno
BlueCloud Africa-Manager @ BlueCloud® by HealthCarePoint
Open to collaborations
Companies pay Yonnie to write a post about their product on LinkedIn.
This page is where they book it. Below: Yonnie's audience, recent posts and price. Naano, the platform behind this page, handles the brief, your approval of the post and the payment.
€57per post, fixed price
You approve the post before it goes live
Looking for Yonnie? View LinkedIn profileA creator yourself? Create your own page
About Yonnie Otieno
Helping Technologies Teams Deliver Faster Using Fit-for-Purpose AI + Quality Systems | Africa Health Technology Ecosystem | BlueCloudX
Health technologies rarely fail because of science. They fail because execution breaks quietly: I work with industry to fix that. My focus is simple: turn complex technology operations into systems — especially across African research environments where alignment, trust, and infrastructure matter most. Across Phase I–IV, work.
HealthTechAISoftware
My LinkedIn audience
- Followers
- 31,215
- Est. median reach
- 225
- Reactions per post
- 2
- Median of recent posts
Public LinkedIn data · Sep 18, 2026
Recent posts
All posts on LinkedInYonnie Otieno
Big Pharma doesn’t sell drugs. It manages a very expensive survival tournament. You start with 10,000+ compounds. Most are politely escorted out of the building. A few reach preclinical development. Even fewer enter clinical trials. Then Phase I asks: “Is it safe?” Phase II asks: “Does it actually work?” Phase III arrives with 3,000 patients, 17 countries, 83 sites, six vendors and a protocol amendment nobody remembers approving. The FDA asks for evidence. HTA asks for value. Payers ask for affordability. Physicians ask for confidence. Patients ask the only question that really matters.. Will this help me? And Finance is standing quietly in the corner asking..? How much runway do we have left?😂 That’s the pharmaceutical business model. Science → Evidence → Approval → Access → Adoption → Revenue → Reinvestment. The interesting part is the last arrow. Revenue from today’s successful medicines helps finance tomorrow’s scientific bets. Because behind every blockbuster you can see… There’s a pharmaceutical graveyard you can’t. Failed molecules. Failed endpoints. Failed trials. Failed regulatory strategies. And probably one Excel spreadsheet still calculating something since 2019. Drug development isn’t a straight pipeline. It’s a capital-intensive evidence machine where science, patients, regulation, access and economics all have to survive the same journey. And somewhere inside that machine… a CRA is still waiting for the site to answer Query #47. 😭 Better science starts the journey. Better evidence keeps it alive. Better execution gets medicine to patients.
25 reactions · 0 commentsViewYonnie Otieno
Big Pharma doesn’t sell drugs. It manages a very expensive survival tournament. You start with 10,000+ compounds. Most are politely escorted out of the building. A few reach preclinical development. Even fewer enter clinical trials. Then Phase I asks: “Is it safe?” Phase II asks: “Does it actually work?” Phase III arrives with 3,000 patients, 17 countries, 83 sites, six vendors and a protocol amendment nobody remembers approving. The FDA asks for evidence. HTA asks for value. Payers ask for affordability. Physicians ask for confidence. Patients ask the only question that really matters.. Will this help me? And Finance is standing quietly in the corner asking..? How much runway do we have left?😂 That’s the pharmaceutical business model. Science → Evidence → Approval → Access → Adoption → Revenue → Reinvestment. The interesting part is the last arrow. Revenue from today’s successful medicines helps finance tomorrow’s scientific bets. Because behind every blockbuster you can see… There’s a pharmaceutical graveyard you can’t. Failed molecules. Failed endpoints. Failed trials. Failed regulatory strategies. And probably one Excel spreadsheet still calculating something since 2019. Drug development isn’t a straight pipeline. It’s a capital-intensive evidence machine where science, patients, regulation, access and economics all have to survive the same journey. And somewhere inside that machine… a CRA is still waiting for the site to answer Query #47. 😭 Better science starts the journey. Better evidence keeps it alive. Better execution gets medicine to patients.
4 reactions · 0 commentsViewYonnie Otieno
GLOBAL TRIALS. VERY UN-GLOBAL DISTRIBUTION. 😂 Clinical research looked at the word “global” and said... Excellent idea. Let’s put most of it over there. The patients are global. The diseases are global. The need for new therapies is global. Then the trial map loads... Africa... “Hello?” 👋🏾 Clinical research...Thank you for your interest. We’ll circle back. 😭 And that is where the joke stops being funny. We talk endlessly about diversity in clinical trials, but diversity cannot magically appear at recruitment. You cannot design the trial, select the countries, choose the sites, allocate the budget, lock the strategy... …and then suddenly remember.. Wait. Do we have Africa? My friend, the protocol is already wearing shoes and heading to the airport. 😂 Real trial diversity starts much earlier: Country strategy. Site development. Investigator capacity. Regulatory readiness. Infrastructure. Sponsor and CRO partnerships. Because you cannot keep concentrating the infrastructure and then hold a meeting to investigate why the trials are concentrated. That CAPA is going to need another CAPA. 😭 Africa doesn't just need more trials. It needs more of the ecosystem that makes trials possible — and makes sponsors confident enough to place them there. The patients went global years ago. Clinical trials are still updating their location settings. 🌍😂 Practical knowledge. In your pocket. If you work in clinical research, pharma, biotech or life sciences, Download the Axon Android app and start learning. https://lnkd.in/d6WMasVf Master the science. Understand the system. Run better trials. Better Trials. Better Patients. A Healthier Tomorrow.
2 reactions · 0 commentsView
Work with Yonnie Otieno
Your collaboration, managed on Naano
- Share your brief with the creator
- Review the content before publication
- Manage your collaboration and payment
How does this price compare? B2B creator rates 2026
Why Sponsors, CROs & Healthcare Innovators Work With Me
What I offer Clinical Research & GCP (ICH E6(R3)) training Protocol-to-operations translation CRA & Clinical Operations Academy AI implementation for Life Sciences Clinical trial process optimization Regulatory and quality systems guidance Educational content & technical infographics Clinical research strategy and consulting How I work First-principles thinking Evidence-driven decisions Systems engineering approach Practical, implementation-focused solutions Clear communication with measurable outcomes Industries Pharmaceutical companies Biotechnology Medical Device CROs Research Sites Universities NGOs HealthTech & AI startups Results Built educational frameworks used by thousands of clinical research professionals. Designed AI-powered workflows that simplify complex clinical operations. Created high-impact visual learning systems for protocols, GCP, monitoring, and regulatory science. Help organizations translate complexity into practical execution. Let's collaborate if you're looking to Train clinical research teams Improve protocol execution Integrate AI into research operations Develop educational content Optimize trial processes Build scalable clinical research systems You should also add these additional sections: What I Offer Clinical Research Consulting • AI for Life Sciences • CRA Training • Protocol Review • Clinical Operations • GCP E6(R3) Training • Regulatory Strategy • Scientific Content Creation • Workshops • Speaking Engagements Why Work With Me I combine scientific rigor with systems thinking, helping organizations improve quality, efficiency, and innovation across the clinical development lifecycle. My work focuses on turning complex scientific concepts into practical solutions that teams can implement immediately.
Storefront by Naano · Create yours
Booking Yonnie Otieno: frequently asked questions
Yonnie Otieno is a B2B LinkedIn creator based in the United States with 31,215 followers, posting about HealthTech, AI, and Software. On Naano, one sponsored LinkedIn post by Yonnie Otieno costs €57, a fixed price per post.
- How much does Yonnie Otieno charge for a sponsored LinkedIn post?
- One sponsored LinkedIn post with Yonnie Otieno costs €57 on Naano. It is a fixed price per post, the amount your brand pays. Compare with the B2B creator rates 2026 report
- How do I book Yonnie Otieno?
- Create a brand account on Naano, choose an offer on this page and send your brief. The price is held when Yonnie Otieno accepts and paid when the post URL is submitted. You can turn on draft approval to review the post before it goes live.
- Can Naano run the campaign for me?
- Yes. With Managed Campaigns, the Naano team sets the strategy, casts the creators, writes the briefs, reviews the drafts, pays the creators and reports results per creator and campaign. It is a three-month programme: a management fee from €3,000 per month, plus a creator budget from €6,000 per month. See Managed Campaigns
Want Naano to run the whole campaign?
The Naano team casts the creators, writes the briefs, reviews every draft with you and reports results per creator. You approve the shortlist and every draft.